Endlyz Targets Parkinson's at the Cellular Level With New Seed Funding
London biotech Endlyz raises Seed 2 funding to restore cellular cleanup systems linked to Parkinson's, aiming to slow disease — not just symptoms.
Summary
Endlyz Therapeutics, a London-based biotech backed by AbbVie and the Dementia Discovery Fund, is developing small-molecule drugs that target the root cellular causes of Parkinson's disease. Rather than managing tremors or stiffness after they appear, the company focuses on restoring lysosomal function — the cell's internal waste-disposal system. Two proteins, ATP13A2 and ATP10B, regulate this cleanup process, and when they fail, toxic waste accumulates in neurons, driving neurodegeneration. Endlyz's Seed 2 round will fund efforts to intervene at this early cellular stage. The company collaborates with KU Leuven, the University of Oxford, and uses AI tools via SandboxAQ to accelerate drug discovery. If successful, this approach could shift Parkinson's treatment from symptom management to genuine disease modification.
Detailed Summary
Neurodegenerative diseases like Parkinson's typically cause irreversible damage long before symptoms appear. By the time tremors or stiffness emerge, neurons have already been deteriorating for years. Most existing treatments address those visible symptoms without altering the underlying disease trajectory. Endlyz Therapeutics is attempting to change that by intervening at the cellular level, years before clinical decline becomes apparent.
The company's core focus is the lysosomal system — essentially the cell's recycling and waste-disposal machinery. When this system functions properly, damaged proteins and cellular debris are cleared efficiently. When it breaks down, toxic waste accumulates. In neurons, which rarely regenerate, this buildup is especially destructive. Endlyz targets two proteins, ATP13A2 and ATP10B, that regulate lysosomal transport. Restoring their function could, in theory, restart the cell's cleanup process and slow or halt neurodegeneration.
Fresh from its Seed 2 financing round, Endlyz has secured backing from major players including AbbVie, Oxford Science Enterprises, the Dementia Discovery Fund, and Parkinson's UK. Scientific leadership includes Professor Peter Vangheluwe of KU Leuven, a specialist in lysosomal transporters, and Professor Richard Wade-Martins of Oxford, who contributes disease modeling expertise. AI-driven drug discovery tools, linked to SandboxAQ, are also integrated into the pipeline.
For longevity-focused readers, this research sits at the intersection of cellular health, aging, and neurodegeneration — all central to healthspan. The lysosomal pathway is closely related to autophagy, a process already well-known in longevity science for its role in clearing cellular damage and extending healthy lifespan in model organisms.
Caveats are significant. Endlyz is still in early-stage development, with no published clinical trial data yet available. Disease-modifying therapies for Parkinson's have historically faced high failure rates in later-stage trials. The science is promising, but translating cellular biology into effective human treatments remains a long and uncertain road.
Key Findings
- Endlyz targets ATP13A2 and ATP10B proteins to restore lysosomal waste-clearance in neurons linked to Parkinson's.
- Seed 2 funding secured from AbbVie, Dementia Discovery Fund, Oxford Science Enterprises, and Parkinson's UK.
- Approach aims to slow or halt Parkinson's progression rather than manage symptoms after they appear.
- AI tools via SandboxAQ are integrated to accelerate small-molecule drug discovery and optimization.
- Lysosomal dysfunction is increasingly recognized as a root cause of multiple neurodegenerative diseases.
Methodology
This is a news report summarizing a company funding announcement and its scientific rationale, not a peer-reviewed study. The source, Longevity.Technology, is a credible industry publication covering longevity biotech. Evidence basis is early-stage preclinical science; no clinical trial data is cited.
Study Limitations
No clinical trial results are available; all findings are based on preclinical science and company communications. Disease-modifying Parkinson's therapies have a poor historical track record in human trials despite promising early data. Readers should consult primary research publications from Vangheluwe and Wade-Martins labs for independent scientific validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.